Evidence map›Paper›PMID 34589724›Full record

ArticleBrain, behavior, & immunity - health2021

Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study.

B Cameron, K Webber, H Li, B K Bennett, F Boyle, P de Souza, N Wilcken, J Lynch, M Friedlander, D Goldstein and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain, behavior, & immunity - health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. The functional TNF-αBreast cancer research and treatment · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

B CameronThe Kirby Institute, UNSW, Sydney, Australia.
K WebberPrince of Wales Hospital Clinical School, Sydney, Australia.
H LiThe Kirby Institute, UNSW, Sydney, Australia.
B K BennettPrince of Wales Hospital Clinical School, Sydney, Australia.
F BoylePatricia Ritchie Cancer Care Centre, Mater Hospital, Sydney, Australia.
P de SouzaSouthside Cancer Care Centre, St George Hospital, Sydney, Australia.
N WilckenWestmead Hospital Cancer Care Centre, Sydney, Australia.
J LynchSt George Hospital, Sydney, Australia.
M FriedlanderPrince of Wales Hospital Cancer Centre, Sydney, Australia.
D GoldsteinThe Kirby Institute, UNSW, Sydney, Australia.
A R LloydThe Kirby Institute, UNSW, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer-related fatigue, mood disturbances, pain and cognitive disturbance are common after adjuvant cancer therapy, but vary considerably between individuals despite common disease features and treatment exposures. A genetic basis for this variability was explored in a prospective cohort.

methodsPhysical and psychological health of women were assessed prospectively following therapy for early stage breast cancer with self-report questionnaires. Participation in a genetic association sub-study was offered. Indices for the key symptom domains of fatigue, pain, depression, anxiety, and neurocognitive difficulties were empirically derived by principal components analysis from end-treatment questionnaires, and then applied longitudinally. Genetic associations were sought with functional single nucleotide polymorphisms (SNPs) in pro- and anti-inflammatory cytokine genes - tumour necrosis factor (TNF)-α (-308 ​GG), interferon (IFN)-ɣ (+874 ​TA), interleukin (IL)-10 (1082 ​GA and -592 CA), IL-6 (-174 ​GC), IL-1β (-511 ​GA).

resultsQuestionnaire data was available for 210 participants, of whom 111 participated in the genetic sub-study. As expected, symptom domain scores generally improved over several months following treatment completion. Tumour and adjuvant treatment related factors were unassociated with either severity or duration of the individual symptom domains, but severity of symptoms at end-treatment was strongly associated with duration for each domain (all p ​< ​0.05). In multivariable analyses, risk genotypes were independently associated with: fatigue with IL-6 -174 ​GG/GC and IL-10 -1082 GG; depression and anxiety with IL-10 -1082 AA; neurocognitive disturbance: TNF-α -308 GG; depression IL-1β (all p ​< ​0.05). The identified SNPs also had cumulative effects in prolonging the time to recovery from the associated symptom domain.

conclusionsGenetic factors contribute to the severity and duration of common symptom domains after cancer therapy.

Indexed as

Breast cancerCancer-related fatigueCytokine gene polymorphismPost-cancer fatigueSymptom domain

Identifiers

PMID34589724
PMCPMC8474532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.